

## SUPPLEMENTAL DIGITAL CONTENT 2 – TABLE S1

**Supplemental digital content: Table S1:** Characteristics of current study participants, compared with individuals from the original study cohort who did not participate in this study

Factor		Participants in current study (n=93)	Non-participants in current study (n=739)	p-value
Mean age at time of primary vaccination, in years		4.32	4.28	0.21
Number of males (percentage of total)		36 (38.7%)	385 (52.1%)	0.02
Primary vaccine received in the original study	Menjugate®	33	281	0.77
	Meningitec®	26	182	
	NeisVac-C®	34	276	
Post-primary MenC antibody responses in the original study	SBA GMT (95% CI)	1114 (488-2542) [n=41]	1180 (965-1444) [n=376]	0.87
	IgG GMC, µg/mL (95% CI)	8.75 (6.64-11.53) [n=82]	8.55 (7.74-9.43) [n=618]	0.87